
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is well-positioned for success due to a strong initial launch of their drug FILSPARI, significant upcoming catalysts with potential for further label expansion, and strong support from key opinion leaders. Financially, the company has a solid cash balance and continues to de-risk their commercial story. However, there are potential risks for the company including the potential for delays or setbacks in commercialization and the possibility of additional capital raises. Overall, the fundamental outlook for Travere Therapeutics is positive and presents a strong opportunity for growth in the rare disease market.
Bears say
Travere Therapeutics is experiencing seasonal headwinds in their 1Q26 total revenue, missing both consensus and Wall Street estimates. With other agents entering the IgAN treatment landscape and an expected mid-20s growth rate, there is potential for positive signals. However, with the management's expectation of nephrologists waiting for patients' next scheduled visit to prescribe the drug, there may be a delay in treatment and potential lower revenue for Filspari in the near term. Additionally, while the recently approved expanded indication for Filspari in FSGS could greatly increase the addressable patient population, it may take some time for these patients to begin treatment, potentially slowing overall revenue growth for the company.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares